Prior experience with bromocriptine in the home cage attenuates locomotor sensitization in rats

Kelsey, John E.; Carlezon, William A.

doi:10.1016/s0166-4328(01)00447-8

Cited by 7 publications

(9 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is substantial evidence in the literature that the development and expression of experience-dependent changes in drug sensitivity involves Pavlovian (stimulusstimulus) associations (Carlezon et al 2000;Kelsey and Carlezon 2002;Robinson and Berridge 2000;Siegel 1976). For example, indicators of sensitization are reportedly stronger and longer-lasting following increases in the number of drug-environment pairings (Michel et al 2003).…”

Section: Discussionmentioning

confidence: 99%

“…Differences in scoring locomotor behavior and differences in the length of time recording the drug-induced behavior likely contribute to the variability of the findings among research groups. Finally, there is disparity in the strength and persistence of sensitized responses when testing occurred in familiar environments (home cage) compared to novel environments (activity chambers) (Crombag et al 1996;Fraioli et al 1999;Kelsey and Carlezon 2002;Robinson and Berridge 2000). Although there is compelling evidence that sensitization involves a strong context-dependent component (Kalivas and Alesdatter 1993;Weiss et al 1989), sensitization also occurs when the drug has been administered in conjunction with minimal exposure to the novel testing environment (Beinfeld et al 2002;Carlezon et al 1995;Todtenkopf et al 2002), suggesting that it also involves context-independent (purely pharmacological) mechanisms.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Contribution of drug doses and conditioning periods to psychomotor stimulant sensitization

Todtenkopf

Carlezon

2006

Psychopharmacology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Contribution of drug doses and conditioning periods to psychomotor stimulant sensitization

Todtenkopf

Carlezon

2006

Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…Doses of the D 1 (SKF81297) and D 4 (PD168,077) agonists have been shown to alter memory performance after systemic administration (Browman et al, 2005;Hotte et al, 2005) and have high selectivity in vivo (Bitner et al, 2006;Gleason and Witkin, 2006). Bromocriptine is 10 and 100 times more potent at D 2 receptors vs D 3 and D 4 receptors, respectively (Seeman and Van Tol, 1993;Perachon et al, 1999), and is behaviorally active at 5.0 mg/kg (Kelsey and Carlezon, 2002). Nafadotride has approximately 10-20 times greater affinity for D 3 vs D 2 receptors (Griffon et al, 1995) but may only be selective at D 3 receptors at doses under 2.0 mg/kg (Levant and Vansell, 1997).…”

Section: Drugs and Satiety Manipulationsmentioning

confidence: 99%

Dopaminergic Modulation of Risk-Based Decision Making

Onge

Floresco

2008

Neuropsychopharmacol

301

299

View full text Add to dashboard Cite

Psychopharmacological studies have implicated the mesolimbic dopamine (DA) system in the mediation of cost/benefit evaluations about delay or effort-related costs associated with larger rewards. However, the role of DA in risk-based decision making remains relatively unexplored. The present study investigated the effects of systemic manipulations of DA transmission on risky choice using a probabilistic discounting task. Over discrete trials, rats chose between two levers; a press on the 'small/certain' lever always delivered one reward pellet, whereas a press on the other, 'large/risky' lever delivered four pellets, but the probability of receiving reward decreased across the four trial blocks (100, 50, 25, 12.5%). In separate groups of well-trained rats we assessed the effects of the DA releaser amphetamine, as well as receptor selective agonists and antagonists. Amphetamine consistently increased preference for the large/risky lever; an effect that was blocked or attenuated by co-administration of either D 1 (SCH23390) or D 2 (eticlopride) receptor antagonists. Blockade of either of these receptors alone induced risk aversion. Conversely, stimulation of D 1 (SKF81297) or D 2 (bromocriptine) receptors also increased risky choice. In contrast, activation of D 3 receptors with PD128,907 reduced choice of the large/risky lever. Likewise, D 3 antagonism with nafadotride potentiated the amphetamine-induced increase in risky choice. Blockade or stimulation of D 4 receptors did not reliably alter behavior. These findings indicate that DA has a critical role in mediating risk-based decision making, with increased activation of D 1 and D 2 receptors biasing choice toward larger, probabilistic rewards, whereas D 3 receptors appear to exert opposing effects on this form of decision making.

show abstract

“…As across dose and across time the acute effects of dopamine agonists on behavior are generally biphasicF behavioral inhibition followed by behavioral excitation (Harkin et al, 2000;Kelsey and Carlezon Jr, 2002;Van Hartesveldt et al, 1992Fit has been hypothesized that sensitization is the mere outcome of tolerance of the drug depressive effects (Baker and Tiffany, 1985;Hinson and Siegel, 1983). However, the present finding that chronic kappa agonist cotreatment with low-dose QNP (0.05 mg/kg) yielded tolerance to the depressive effects of QNP without full-blown sensitization (as evidenced by lack of a sensitized response to higher doses of QNP; Figure 5) falsifies this hypothesis.…”

Section: A Model Of Qnp Sensitizationmentioning

confidence: 99%

“…The acute effects of dopamine agonists on locomotion are generally biphasic, with locomotor depression followed by locomotor excitation (Harkin et al, 2000;Kelsey and Carlezon Jr, 2002;Van Hartesveldt et al, 1992. It had been proposed that the depressive effects of dopamine agonists probably reflect stimulation of presynaptic dopamine receptors (Clark et al, 1985;Richtand et al, 2001;Starr and Starr, 1986).…”

Section: Introductionmentioning

confidence: 99%

Kappa-Opioid Agonist U69593 Potentiates Locomotor Sensitization to the D2/D3 Agonist Quinpirole: Pre- and Postsynaptic Mechanisms

Perreault

Graham

Bisnaire

et al. 2005

Neuropsychopharmacol

View full text Add to dashboard Cite

To assess whether the development and expression of behavioral sensitization to the dopamine D2/D3 agonist quinpirole (QNP) is influenced by coadministration of the kappa opioid receptor agonist U69593, rats received every 3-4 days for a total of 10 treatments an injection of U69593 (0.3 mg/kg) together with an injection of either a postsynaptic (0.5 mg/kg) or a presynaptic dose of QNP (0.05 mg/ kg); locomotor activity was measured after each treatment. Control rats were injected as appropriate with QNP, U69593, and vehicle/ saline. Following chronic treatment, dose-response profiles to QNP were obtained to assess the expression of sensitization; the effect of U69593 on locomotor activity in animals already sensitized to QNP was also assessed. Results showed that cotreatment of U69593 with a postsynaptic dose of QNP doubled the speed and magnitude of sensitization to QNP, while U69593 cotreatment with a presynaptic dose of QNP switched the effects of QNP from locomotor depression to locomotor sensitization. However, U69593 cotreatment with a presynaptic dose of QNP changed a different set of measures of sensitization than did cotreatment with a postsynaptic dose of the dopamine agonist. Together, findings suggest that sensitization to QNP is not a unitary phenomenon but has components that are relatively independent, mediated by distinct pre-and postsynaptic mechanisms and modulated by kappa receptor activity.

show abstract

Prior experience with bromocriptine in the home cage attenuates locomotor sensitization in rats

Cited by 7 publications

References 28 publications

Contribution of drug doses and conditioning periods to psychomotor stimulant sensitization

Contribution of drug doses and conditioning periods to psychomotor stimulant sensitization

Dopaminergic Modulation of Risk-Based Decision Making

Kappa-Opioid Agonist U69593 Potentiates Locomotor Sensitization to the D2/D3 Agonist Quinpirole: Pre- and Postsynaptic Mechanisms

Contact Info

Product

Resources

About